Shijiazhuang International Biomedical Park, Hebei Province. Photo by Liang Zidong Bright**.
Workers work in the pharmaceutical preparation production line of North China Pharmaceutical Beiyuan Branch. Photo by Liang Zidong Bright**.
The staff conducted drug experiments in the first-class quality inspection center of Shenwei Pharmaceutical Group. Photo by Liang Zidong Bright**.
In the depths of winter, the chill is already thick. In Shijiazhuang City, Hebei Province, the scientific researchers of biomedical enterprises are busy and busy, and the production links are in full swing, full of vitality and vitality. In the antibody discovery room of CSPC Pharmaceutical Group, Ding Huandi, director of the department, is busy checking the latest experimental resultsIn the preparation R&D room of Hebei Naco Biotechnology, staff member Liu Xin is concentrating on operating the pipette and debugging the proportion of the injection ......
In recent years, Shijiazhuang has continued to promote the high-quality development of the biomedical industry and accelerated the cultivation of a 100-billion-level biomedical industry cluster. At present, the city has become an important pharmaceutical production base in Hebei Province and even the whole country, forming a biomedical industry system led by biotechnology drugs, chemical drugs as the main body, modern Chinese medicine as the characteristics, and high-end medical devices as the supplement.
On May 12, 2023, the general secretary emphasized during his inspection in Shijiazhuang City that the biomedical industry is a strategic emerging industry related to the national economy and people's livelihood. It is necessary to strengthen the capacity building of basic research and scientific and technological innovation, and firmly grasp the lifeblood of the development of the biomedical industry in our own hands. It is necessary to adhere to the supremacy of the people and the supremacy of life, develop and produce more "Chinese medicines" suitable for the genetic inheritance and physical fitness characteristics of Chinese, especially to strengthen the inheritance and innovative development of traditional Chinese medicine.
Accelerate the cultivation of 100-billion-level biomedical industry clusters, so that batches of innovative achievements can emerge. Recently, the Guangming ** research team came to Shijiazhuang to investigate the development of the biomedical industry.
1.String "beads" into a chain of industrial clusters to store energy.
Stepping into the 1st floor of Building A12 of Shijiazhuang International Biomedical Park, the dust-free production workshop of Donghai Pharmaceutical (Hebei)** is spacious and bright, and the staff wearing protective clothing check the operation of the machine from time to time, and the two soft capsule production lines are working intensively.
We are the first branch of the head office in the country to have a soft capsule production base. Zhang Yanan, director of the comprehensive office, took the members of the research team all the way, and she said that it was because of the advantages of Shijiazhuang's deep industrial foundation and perfect supporting services that the company chose to "set up camp" in the international biomedical park with peace of mind.
Enterprises gather to share opportunities. Zhang Yanan introduced in detail that the increasingly perfect industrial chain of Shijiazhuang City has brought more opportunities for win-win cooperation between enterprises. In fact, in July this year, before the company's soft capsule production line was put into production, they entrusted the production of calcium carbonate chewable tablets to another local pharmaceutical company with the help of relevant departments in the high-tech zone. "In this way, we don't have to build new production lines and buy production equipment, which saves money and effort, and cooperative enterprises can also increase orders and obtain benefits, which can be described as killing multiple birds with one stone. ”
Since the start of construction in 2021, 2The 80,000-acre park has built a full-chain industrial ecosystem integrating R&D, incubation, industrialization, sales and supporting services, attracting a large number of entrepreneurs with ideals and beliefs, and bringing together a large number of high-quality biomedical enterprises. Qin Jihui, Secretary of the Party Group of the Management Committee of Shijiazhuang International Biomedical Park, introduced that at present, 243 biomedical enterprises have gathered in the park, and a total of 65 biomedical projects have been undertaken in Beijing and Tianjin R&D and Shijiazhuang transformation.
The vigorous development of Shijiazhuang International Biomedical Park benefits from the good development ecology and deep industrial foundation.
Shijiazhuang, known as the "pharmaceutical capital of North China", is one of the first national bio-industry bases, with 5 of the top 100 enterprises in China's pharmaceutical industry and 189 enterprises in the biomedical industry, with a strong industrial foundation.
Based on the regional resource endowment and industrial foundation, Shijiazhuang takes the biomedical industry as an important support to promote high-quality development, helps to pool innovative resources, and promotes the cluster development of biomedical industries. Wu Shuke, a second-level researcher in Shijiazhuang City, said that now, in Shijiazhuang, a number of specialized, special and new "little giant" enterprises cover biomedicine, medical devices and other fields. Shenwei Pharmaceutical and other county-level characteristic industrial cluster "leader" enterprises have given full play to the role of demonstration and leadership, and have driven the rapid development of a number of supporting enterprises. At the same time, the construction of key projects such as the "lighthouse factory" of CSPC's intelligent manufacturing is in full swing, and the development momentum is full.
In Shijiazhuang Economic and Technological Development Zone, the construction of the "Lighthouse Factory" project of CSPC Pharmaceutical Group's intelligent manufacturing with a planned total investment of 3 billion yuan is being stepped up, and the main body has been capped, and the exterior decoration and product planning and design are underway. Wang Jianming, senior director of the engineering management center of CSPC Pharmaceutical Group, explained that the "lighthouse factory" is Industry 4The best practice factory with 0 technology application represents a high level of global intelligent manufacturing. The project is built in accordance with intelligent manufacturing and international standards, and applies new technologies such as 5G, artificial intelligence, and big data, which can realize continuous manufacturing and unmanned operation. After the completion of the construction, it will focus on the production of high-end innovative drugs with independent intellectual property rights, and strive to build a world-class innovative drug production base.
In order to create a good development ecology and enhance the development momentum of biomedical enterprises, in recent years, Shijiazhuang has built a regional industrial layout focusing on high-tech zones and supporting economic development zones, Luancheng, Zhaoxian and Jinzhou, and has built a biomedical industry system led by biotechnology drugs, chemical drugs as the main body, modern Chinese medicine as the characteristics, and high-end medical devices as the supplement, so that more and more high-quality biomedical enterprises can take root and grow here.
In Zhao County, the production workshop of Renhe Yikang Group is spacious and bright, the workers are busy, and a group of drugs on the production line are accurately injected into the bottle, waiting for the next step of quality inspection and packaging. "In the past two years, the Group has obvious advantages in the R&D and manufacturing of APIs, injections, inhalation preparations, small infusion preparations, oral liquid preparations and solid preparations of insoluble drugs, and the market is in short supply. Li Guoying, chairman of Renhe Yikang Group, said that in 2022, the group's operating income will reach 1.5 billion yuan, and the tax will be 1100 million yuan.
At present, there are 29 pharmaceutical enterprises in Zhao County, including 20 enterprises above the designated size and 12 enterprises with R&D centers at or above the provincial and municipal levels, forming the foundation for the development of the whole industrial chain of 'intermediates-APIs-preparations-pharmaceutical packaging'. Bai Yinghui, deputy secretary of the Party Working Committee and executive deputy director of the Management Committee of Zhao County Economic Development Zone, introduced.
In the first half of this year, the operating income of Shijiazhuang's pharmaceutical industry increased by 156%, becoming one of the main engines driving the growth of the city's industrial economy. Wu Shuke said.
2.Wu Gao Fengzhi allows talents to "live in peace" and "feel at ease".
The reason why Shijiazhuang was chosen is because of the strong policy support, the sufficient attention to talents, the good prospects for industrial development, and the creation of space for personal development. In Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Dr. Chen Daohong, who had just finished his busy work from the laboratory, explained the reason why he chose to come to Shijiazhuang and Zhengding for development.
Chen Daohong is a high-level scientific and technological innovation and entrepreneurship talent introduced by Zhengding County, and after returning from the United States in 2018, he went to work in Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Not long ago, the "sildenafil bioequivalence test" project led by him successfully passed the acceptance of Shijiazhuang Science and Technology Bureau and relevant experts.
After getting the talent green card in Shijiazhuang, not only the housing problem was successfully solved, but also there were preferential treatment in medical treatment, transportation, etc., and even the family members could enjoy a series of preferential treatment, completely eliminating worries, all we had to think about was how to display our talents and develop their careers well!Chen Daohong bluntly said that Shijiazhuang's talent policy is very warm and intimate, and it is full of attraction to talents of different ages, different levels and different fields.
In recent years, Shijiazhuang City has taken talent construction as a basic work, created a talent ecology of "near and far", deepened the reform of the talent development system and mechanism, cultivated, introduced and made good use of talents in an all-round way, and promoted the talent work to a new level.
According to the Shijiazhuang talent green card policy, all the introduced card-holding talents can not only enjoy preferential policies such as education, medical care, and household registration, but also enjoy rent subsidies and the guarantee of living in talent apartments, so that all kinds of talents can take root in Shijiazhuang with peace of mind.
Up to now, the city has issued a total of 1,051 talent green card A cards, 16,754 B cards, and 77,795 county (city, district) cards. The talent green card has become a "golden business card" created by Shijiazhuang to attract talents and gather talents, providing strong support for all walks of life, especially the biomedical industry.
Talents must be introduced, and they must be retained and used well.
In June this year, Shijiazhuang City held the "Outstanding Young Talents Support the Construction of the Development Zone Mobilization Meeting", and selected the first batch of 40 outstanding young professionals from the city's on-the-job cadres to go to the front line of economic development to support the construction of the development zone and industrial development, especially the development of the biomedical industry.
Shijiazhuang is making every effort to build a 100-billion-level biomedical industry cluster, and now is the time for me to apply what I have learned and show my strength. Ye Pan, a doctor of biology from Tsinghua University, came to Shijiazhuang to work in 2018, has experience in multiple departments and positions, and also has a deeper understanding of Shijiazhuang's economic and social development in recent years. Talking about being selected to work in Shijiazhuang High-tech Zone, he said that in the future, he will give full play to his professional advantages, do his best to do a good job, and contribute to the development of the biomedical industry in Shijiazhuang High-tech Zone.
Focusing on talent management, evaluation, incentives, mobility and other links, we will continue to "decentralize power" to break down institutional barriers and remove identity barriers.
Leading talents can receive up to 100 million yuan in project support funds;College graduates can receive a maximum of 50,000 yuan settling-in subsidy;High-level talents who come to Shijiazhuang to carry out technology research and development and achievement transformation and incubation can directly settle in incubators such as Shijiazhuang Science and Technology Innovation Service Center and enjoy policy support ...... in terms of R&D equipment, venues, and human resource services
In May this year, Shijiazhuang issued the "Several Measures (Trial) on Further Increasing the Introduction of Talents and Promoting the Construction of Modern, International and Beautiful Provincial Capital Cities (Trial)", and the 12 new policies for talents are full of gold.
On November 3, Shijiazhuang City once again issued the "Several Measures on the In-depth Implementation of the Strategy of Strengthening the City with Talents in the New Era (Trial)".
For the first time, an angel investment guide for the transformation of scientific and technological achievements with a scale of 2 billion yuan was established, and a talent venture capital of 10 billion yuan was set up in stagesThe loan amount of Shijiazhuang Talent Loan has been increased from a maximum of 50 million yuan to 100 million yuanIn addition to enjoying subsidies for house purchase and rent, B card talents who work in enterprises will also receive a one-time settlement subsidy of up to 50,000 yuan......The 15 new policies for the selection of talents without sticking to one pattern have aroused widespread concern in society.
We start to break the ice from the top-level design, closely follow the biomedical industry exhibition and talent needs, take precise talent introduction, precise docking industry development, and accurate meeting of talent needs as the core concept, rely on the industrial chain to lay out the talent chain, and drive the whole society to form a good atmosphere of respect for knowledge and talents. Lv Zhilin, executive deputy director of the Organization Department of the Shijiazhuang Municipal Party Committee, said that Shijiazhuang will vigorously implement the strategy of strengthening the city with talents in the new era and the strategy of innovation-driven development, gather a group of leading scientific and technological talents and innovation teams who master key core technologies and can lead the future development, attract a group of outstanding graduates and young talents from colleges and universities, and provide strong talent and intellectual support for accelerating the cultivation of 100 billion-level biomedical industry clusters.
3.Science and technology empower the growth of the main body of innovation.
Not long ago, Shijiazhuang No. 4 Pharmaceutical Group's two special products - pentoxifylline sustained-release tablets, sti-pentanol raw materials and their dry suspensions have been approved, so far, the group has obtained 62 approvals for various new products this year, of which 15 new products have been approved in the fourth quarter alone.
The flowering of scientific and technological innovation is a vivid portrayal of the rapid development of Shijiazhuang's biomedical industry in recent years.
CSPC Pharmaceutical Group invests nearly 4 billion yuan in R&D every year, and its R&D expenses in the first three quarters of this year are 367.8 billion yuan, an increase of 25 percent year-on-year9%, about 60 key drugs under development have entered the clinical or application stage. In the antibody discovery room of CSPC Pharmaceutical Group, Ding Huandi, director of the department, introduced to the research team that they rely on eight platforms such as nano preparation drug platform and mRNA platform, focusing on the six major fields of tumor, psychiatric nerve, cardiovascular, immune and respiratory, metabolism and anti-infection, to carry out the research and development of innovative drugs, and submit more than 1,000 patent applications every year. In the first three quarters of this year, the group launched 4 innovative drugs, and more than 40 innovative drugs are expected to be launched in the next five years.
Heavy research and development, strong innovation, scientific and technological achievements have been implemented. In the North China Pharmaceutical Research Institute, Gao Jianzheng, deputy general manager of North China Pharmaceutical Co., Ltd., discussed with the R&D personnel the promotion plan of the rabies virus monoclonal antibody combination preparation. Gao Jian introduced that last year, they successfully developed a new national class I drug, omutevimab injection, which is the first approved monoclonal antibody drug in the field of anti-infection in China. The rabies vaccine can only be produced after 7 days after the animal is injured, and the drug itself is a high-potency antibody, which takes effect immediately after injection, and the protective efficacy against rabies is close to 100%.
The capacity building of basic research and scientific and technological innovation has been continuously strengthened, the main body of innovation has developed and expanded, and innovative achievements have emerged one after another.
In March this year, the project of "Establishment and Industrialization of Key Technology System for Polyethylene Glycol Designated Modification of Recombinant Protein Drugs (Jinyouli)" declared by CSPC Pharmaceutical Group was awarded the Commendation Award of China Industry Award. The drug is the first long-acting recombinant human granulocyte-stimulating factor injection with independent intellectual property rights in China, and is a national class I new drug for biological products.
In the peptide laboratory of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Pharmaceutical Research Institute, various analysis and testing instruments on the table are running smoothly, and R&D personnel are stepping up the purification of ebenatide.
Ebenatitide is a national class I new drug for type ** diabetes, which has been included in the national major science and technology projects, and the drug adopts advanced technologies such as solid-phase synthesis and chromatography purification, with controllable quality, and has completed phase clinical trials and is expected to be approved for marketing in 2024. Sun Peng, president of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. *** Research Institute, said that ebenatide can be extended from the original once-daily administration to once-a-week administration, which can greatly reduce the inconvenience of frequent injection and administration in diabetic patients.
The advantages of key industries are concentrated, and the release of innovation momentum is accelerated. In Shijiazhuang International Biomedical Park, a large number of high-quality biopharmaceutical companies such as WuXi Biologics and Huapu Biologics have settled in ......At present, the high-tech zone has built an industrial structure dominated by innovative drugs, antibody drugs, modern Chinese patent medicines and medical devices, with 1,800 biomedical market entities and more than 400 new drugs under development.
Promoting the digital transformation of traditional industries is an important way for the manufacturing industry to achieve high-quality development. Through digital transformation and intelligent production, Shenwei Pharmaceutical Group has completed the data integration of production equipment and laboratory inspection instruments, and realized the digital and lean operation and management of the enterprise. Hebei Erhaitai Pharmaceutical Co., Ltd. made full use of the software and hardware advantages of the GMP production line of lyophilized preparations to carry out digital upgrading, optimized the lyophilization time from 60 hours to 25 hours and 26 hours, increased production efficiency by 30%, and reduced energy consumption per unit of output value by 12%.
The introduction of high-end "living water" will empower and increase the momentum of accelerating high-quality development.
On November 15, Shijiazhuang Municipal People** signed a comprehensive cooperation framework agreement with Tsinghua University. Tsinghua University will technically support Shijiazhuang to build a "biomedical industry innovation center", provide order-based R&D services, and promote the implementation of a number of industrialization and practical projects. "Accelerating the transformation of innovation achievements and enhancing core competitiveness is the 'engine' to promote the high-quality development of the industry. Zhang Donghai, Secretary of the Party Group and Director of Shijiazhuang Municipal Bureau of Industry and Information Technology, said that Shijiazhuang has 18 national innovation platforms and 167 provincial innovation platforms in the biomedical industry, and Shijiazhuang will continue to adhere to innovation-driven and promote the high-quality development of the biomedical industry in the future.
4.Experience and inspiration.
Shijiazhuang City in-depth study Xi implementation of the general secretary of Shijiazhuang when the important instructions for the development of the biomedical industry, and actively promote the implementation of relevant policies, highlight enterprise innovation, and make every effort to promote the continuous expansion of the scale of the biomedical industry, to achieve the rapid development of the biomedical industry, the research team believes that there are several experiences and enlightenment worth considering.
The business environment has been further improved, and the efficiency of approval has been accelerated. Adhere to the blade inward and self-revolution, according to the World Bank standards, refine 209 specific tasks, and promulgate the "Shijiazhuang City Regulations on Optimizing the Business Environment", which was officially implemented on May 1Vigorously promote the "Internet, reduce time, and facilitate the people", 100% of the administrative examination and approval matters are handled online, and more than 76% of the examination and approval time limit is better than that of similar provincial capitals, and the examination and approval efficiency ranks among the first phalanx in the country.
In order to promote the landing and production of the Donghai pharmaceutical project as soon as possible, Shijiazhuang High-tech Zone organized various departments to hold on-site coordination meetings, open up a green channel, and handle the approval procedures for fire protection and environmental impact assessment as soon as possible, and it took only one year from the project approval to production. Zhengding County implements a new model of examination and approval system reform of "combination of correspondence + commitment system" for the county's investment and capital selection projects. Help Houde Hanfang Medical Device Co., Ltd. to achieve the production project of foot stickers and warm stickers to achieve "start construction as soon as the land is acquired".
The policy red envelope is landed, and the real gold ** support. The "Several Measures to Support the First Breakthrough of the New Generation of Electronic Information Industry and Biomedical Industry" was introduced, and a leading industry development of 20 billion yuan and a special fund of 1 billion yuan per year were set up, and the R&D and production of Class I innovative drugs were given a maximum of 1200 million yuan in rewards. At the same time, Shijiazhuang City has issued a series of policies such as high-tech landing rewards, gazelle enterprise recognition awards, and industrial innovation center work guidelines.
Build a "reservoir" of talents and build a strong "hard core" for development. Always keep in mind that innovation is the first driving force and talent is the first resource, and implement the talent green card policy. Shijiazhuang regards the construction of talents as the basic work. All the introduced cardholders can not only enjoy preferential policies such as education, medical care, and household registration, but also enjoy rent subsidies and the guarantee of living in talent apartments. In order to stimulate the innovation and creativity of talents, promote the gathering of talents, and form a good pattern of leading the industry, gathering talents in the industry, and integrating the development of production and talent.
With the help of the talent policy, Shijiazhuang was selected as the "2022 China's Best Talent Introduction City".Yiling Pharmaceutical's project "Construction of Traditional Chinese Medicine Context Theory and Its Guidance for the Prevention and Treatment of Microvascular Lesions" won the first prize of the 2019 National Science and Technology Progress AwardCSPC's project "Establishment and Industrialization of Key Technology System for Polyethylene Glycol Site-Directed Modification of Recombinant Protein Drugs" won the second prize of the 2020 National Science and Technology Progress Award, and the pattern of relying on talents and innovation to drive industrial development has taken shape.
Strengthen the chain and supplement the chain to create a new highland for the industry. Based on the regional resource endowment and industrial foundation, Shijiazhuang City regards the biomedical industry as an important support for promoting high-quality development, strengthens the supporting role of projects, promotes the rapid development of the biomedical industry, and promotes the rapid rise of biomedical industry clusters with strong market competitiveness by extending the chain and strengthening the chain.
In the first three quarters of this year, Shijiazhuang's biomedical industry achieved a year-on-year increase of 102%。At present, the operating income of the city's biomedical industry accounts for more than 60% of the operating income of the province's biomedical industry.
Author: Guangming ** research group, research team members: Geng Kunli, researcher of Hebei Medical Humanities and Social Science Research Base, Wang Yankun, second-level researcher of Hebei Academy of Social Sciences, Geng Jiankuo, Chen Yuanqiu, reporters of this newspaper, Zhao Yuanjun and Shi Zixian, correspondents of this newspaper).